联用治疗黑色素瘤.pdfVIP

NIH Public Access Author Manuscript Cell Death Dis. Author manuscript; available in PMC 2010 December 28. N Published in final edited form as: I H Cell Death Dis. 2010 August 26; 1(8): e67. doi:10.1038/cddis.2010.43. - P A A u Pegylated IFN-α sensitizes melanoma cells to chemotherapy and t h o r causes premature senescence in endothelial cells by IRF-1 M a n mediated signaling u s c r 1 1 2 3 i Meenakshi Upreti , Nathan A. Koonce , Leah Hennings , Timothy C. Chambers , and p t Robert J. Griffin1 1Department of Radiation Oncology, University of Arkansas for Medical Sciences, Little Rock, AR 2Department of Pathology, University of Arkansas for Medical Sciences, Little Rock, AR 3Department of Biochemistry Molecular Biology, University of Arkansas for Medical Sciences, Little Rock, AR N I H Abstract - P A Pegylated Interferon-α2b (pIFN-α) is an integral part of the drug regimen currently employed A against melanoma. Interferon Regulatory Factor-1 (IRF-1) plays an important role in the u transcriptional regulation of the IFN response, cell cycle and apoptosis. We have studied pIFN-α t h o induced responses when combined with the chemotherapy agent, vinblastine in tumor and r endothelial cell lines and the connection to IRF-1 signaling. Levels of IRF-1/IRF-2 protein M a expression were found to be decreased in tumor versus normal tissues. pIFN-α induced IRF-1 n signaling in human